Form D · Pharmaceuticals
Exalys Therapeutics, Inc.
San Diego, CA · CIK 0001808911
Offering snapshot reported Apr 10, 2020 · SEC filing
- Reported sold
- $4M Offering amount: $25M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 3, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 10, 2020 | Initial | $4,000,186 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-364777
Source: Form D, filed Apr 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rick Orr | Director |
| Dennis Podlesak | Director, Executive |
| Lynne Rollins | Executive |
| Michael Sanders | Executive |
| Brian Taylor Slingsby | Director |
| Takeshi Takahashi | Director |
| Nicole Vitullo | Director |
| Eckard Weber, M.D. | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
12481 High Bluff Drive Suite 150
San Diego, CA, 92130
San Diego, CA, 92130